Inhibrx | Investors - News Releases

News Releases

Month Year

Month Year

Nov 5, 2020

Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences
Aug 21, 2020

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Aug 18, 2020

Inhibrx Announces Pricing of Initial Public Offering of Common Stock
Jan 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40
Sep 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

-INBRX-109 was well-tolerated; a maximum tolerated dose was not reached-

Show per page

Back To Top